WeVote
Log In

Bill

CP

Bill

HB 5175

AN ACT CONCERNING PRESCRIPTION DRUG COSTS.

2025 Regular Session Introduced by Chris Poulos

Connecticut bill HB 5175 addresses prescription drug costs through regulatory mechanisms currently under committee review.

REF. TO JOINT COMM. ON Insurance and Real Estate
#consumerprotection #drugs
0
WeVote Research Nonpartisan
Bill Summary · HB 5175

Legislative bill overview

HB 5175 is a Connecticut bill designed to address prescription drug costs, though the specific mechanisms are not detailed in the available information. The bill was introduced by Representative Chris Poulos and is currently under review by the Joint Committee on Insurance and Real Estate as of January 14, 2025.

Why is this important

Prescription drug affordability is a significant concern for Connecticut residents, particularly seniors and those with chronic conditions who face high out-of-pocket costs. Legislative action in this area can influence insurance coverage requirements, drug pricing negotiations, or cost-sharing mechanisms that directly affect healthcare expenses for vulnerable populations.

Potential points of contention

  • Pharmaceutical industry concerns: Drug manufacturers may oppose price controls or negotiation requirements that could reduce revenues or affect research and development funding
  • Insurance market impacts: Requirements on insurers regarding drug coverage or cost-sharing could increase premiums or alter plan structures
  • Implementation scope: Disagreement may exist over whether the bill applies only to state programs, all insurers, or specific drug categories, affecting its practical reach

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.